mapatumumab experimental human monoclonal antibody undergoing clinical trials treatment targets also known expressed surface many tumor cell drug discovered cambridge antibody technology astrazeneca human genome sciences glaxosmithkline result collaboration two companies exploitation cats phage display technology early work two companies indicated mapatumumab induced cell death multiple tumor types vitro phase clinical trial demonstrated safety tolerability mapatumumab cancer patients advanced solid tumors nonhodgkin lymphoma supported evaluation phase clinical trials single agent combination phase clinical trial mapatumumab well tolerated could administered safely patients advanced nonsmallcell lung cancer nsclc advanced colorectal cancer stable disease observed number nsclc two phase clinical trials mapatumumab combination chemotherapy well tolerated patients advanced solid tumors partial response observed number patients results phase clinical trial demonstrated mapatumumab well tolerated capable producing clinical responses administered monotherapy patients advanced nonhodgkin lymphoma according hgs reported initial results randomised phase trial mapatumumab combination bortezomib advanced multiple however mapatumumab failed midstage study difference disease response progressionfree survival rates patients receiving drug multiple myeloma control august initial dosing patients randomized phase trial mgkg mgkg combination paclitaxel carboplatin firstline therapy patients advanced nonsmallcell lung cancer nsclc initial data study anticipated july hgs initiated dosing randomized phase trial combination nexavar sorafenib patients advanced hepatocellular cancer accounts liver httpsenwikipediaorgwikimapatumumab